These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 19239686)

  • 21. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
    Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
    Enomoto Y; Yamashita S; Yoshinaga Y; Fukami Y; Miyahara S; Nabeshima K; Iwasaki A
    Tumour Biol; 2014 Nov; 35(11):11021-5. PubMed ID: 25095982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
    Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
    Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
    Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
    Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
    Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
    BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
    Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
    Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
    Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
    Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low protein expression of MET in ER-positive and HER2-positive breast cancer.
    Zagouri F; Brandstetter A; Moussiolis D; Chrysikos D; Dimitrakakis C; Tsigginou A; Marinopoulos S; Zografos GC; Sergentanis TN; Dimopoulos MA; Filipits M
    Anticancer Res; 2014 Mar; 34(3):1227-31. PubMed ID: 24596364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.
    Albasri A; Aleskandarany M; Benhasouna A; Powe DG; Ellis IO; Ilyas M; Green AR
    Breast Cancer Res Treat; 2011 Feb; 126(1):47-54. PubMed ID: 20390342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas.
    Paul Wright G; Davis AT; Koehler TJ; Melnik MK; Chung MH
    Ann Surg Oncol; 2014 Oct; 21(11):3497-503. PubMed ID: 24838367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
    Puzovic V; Brcic I; Ranogajec I; Jakic-Razumovic J
    Neoplasma; 2014; 61(4):439-46. PubMed ID: 24645837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
    Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
    Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.